{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:36Z","timestamp":1793286216024,"version":"4.5.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A man in his early 50s presented with small bowel obstruction, requiring emergency laparoscopic small bowel resection for the metastatic melanoma of the jejunum with no identifiable primary lesion. One week after his first treatment with ipilimumab and nivolumab, he presented with diffuse abdominal pain, constipation, and fatigue. A computerized tomography scan did not identify a cause for his symptoms. This was rapidly followed by thrombocytopenia on day 11 and then anemia. He commenced intravenous corticosteroids for a suspected diagnosis of immune-related thrombocytopenia. On day 15, a generalized onset motor seizure occurred, and despite plasmapheresis later that day, the patient died from fatal immune-related thrombotic thrombocytopenic purpura (TTP). This was confirmed with suppressed ADAMTS13 (&amp;lt;5%) testing on day 14. Immune-related TTP is a rare and, in this case, fatal immune- related adverse event. Further studies are required to identify additional immunosuppressive management for immune-related TTP.<\/jats:p>","DOI":"10.3389\/fimmu.2022.871217","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T13:08:13Z","timestamp":1650460093000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma"],"prefix":"10.3389","volume":"13","author":[{"given":"W. J.","family":"Mullally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. E.","family":"Abernethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Landers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-Based Combinations for the Treatment of Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomised Clinical Trials","volume":"154","author":"Massari","year":"2021","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated Overall Survival (OS) Data From a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) Versus Sorafenib (Sor) in Patients (Pts) With Unresectable Hepatocellular Carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2021.1948532","article-title":"Lenvatinib Plus Pembrolizumab: The Next Frontier for the Treatment of Hepatocellular Carcinoma","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety Evaluation of Immune-Based Combinations in Patients With Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in Patients With Melanoma Receiving Immune Checkpoint Inhibitor Therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic Microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13764","article-title":"Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis and Potential Novel Therapeutics","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-Related Microangiopathic Hemolytic Anemia: Clinical and Laboratory Features in 168 Reported Cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Med (Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02704.x","article-title":"Microangiopathic Haemolytic Anaemia in Metastasizing Malignant Tumours Is Not Associated With A Severe Deficiency of the Von Willebrand Factor-Cleaving Protease","volume":"113","author":"Fontana","year":"2001","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2464619","DOI":"10.1155\/2018\/2464619","article-title":"Thrombotic Thrombocytopenic Purpura Due to Checkpoint Inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab After Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant Metastasis-Free Survival Results From a Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.871217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T13:08:15Z","timestamp":1650460095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.871217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2022.871217"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.871217","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"article-number":"871217"}}